- Previous Close
11,940.00 - Open
11,850.00 - Bid 11,810.00 x --
- Ask 11,840.00 x --
- Day's Range
11,800.00 - 12,200.00 - 52 Week Range
11,050.00 - 29,700.00 - Volume
21,446 - Avg. Volume
36,769 - Market Cap (intraday)
154.09B - Beta (5Y Monthly) 0.70
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date Aug 12, 2024 - Aug 16, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 27, 2019
- 1y Target Est
--
HansBiomed Corporation, together with its subsidiaries, engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies. The company provides ExFuse, a demineralized bone matrix with cancellous bone gel/putty; BellaFuse, a demineralized bone matrix; Genesis, a cancellous sponge block/filler; Pedi-Stick, a demineralized cortical bone stick; SureChip, a cancellous bone chip; OsteoGrow, a demineralized bone matrix inserter; BellaCell HD, an allograft dermal product that transplanted in a patient whose skin has been lost due to breast cancer; and SureDerm, an acellular dermal matrix. It also offers BELLAGEL, a breast prosthesis, internal, and gel-filled solution; MINT Lift, a PDO thread; EZ-Tcon solution; Lion HT/HN, a hair transplanter body/needle; and Scar Clinic, a scar management solution. The company was formerly known as Hans Medical Corp. and changed its name to HansBiomed Corporation in June 2000. The company was founded in 1990 and is headquartered in Seoul, South Korea.
www.hansbiomed.comRecent News: 042520.KQ
Performance Overview: 042520.KQ
Trailing total returns as of 6/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 042520.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 042520.KQ
Valuation Measures
Market Cap
155.06B
Enterprise Value
179.20B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.87
Price/Book (mrq)
2.15
Enterprise Value/Revenue
2.29
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-12.78%
Return on Assets (ttm)
-1.44%
Return on Equity (ttm)
-16.76%
Revenue (ttm)
78.29B
Net Income Avi to Common (ttm)
-10B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
7.65B
Total Debt/Equity (mrq)
43.83%
Levered Free Cash Flow (ttm)
-3.44B